Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study

Sagar S. Patel, MD, Kwang Woo Ahn, PhD, Manoj Khanal, BS, MS, Caitrin Fretham, MPH, Celalettin Ustun, MD, Betty K. Hamilton, MD, Navneet S. Majhail, MD MS, Shin Mineishi, MD, Bipin N. Savani, MD, Mohamed Sorror, MD MSc, Edward A. Stadtmauer, MD FACP, Brent Logan, PhD, Marcelo C. Pasquini, MDMS, Saurabh Chhabra, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140503

Published: 2020

Journal Articles

Expanded Comorbidity Definitions Improve Applicability of the Hematopoietic Stem Cell Transplantation-Comorbidity Index for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation

Brian D Friend, MD, Larisa Broglie, MD MS, Brent Logan, PhD, Caitrin Fretham, MPH, Gary J. Schiller, MD, Bipin N. Savani, MD, Edward Stadtmauer, Saurabh Chhabra, MD, Marcelo C. Pasquini, MDMS, Monica Thakar, MD, Mohamed Sorror, MD MSc

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-140778

Published: 2020

Journal Articles

Expanded Comorbidity Definitions Improve Application of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for Children and Young Adults with Non-Malignant Diseases Receiving Allogeneic Hematopoietic Cell Transplantation

Larisa Broglie, MD MS, Brian D Friend, MD, Brent Logan, PhD, Caitrin Fretham, MPH, Gary J. Schiller, MD, Bipin N. Savani, MD, Edward A. Stadtmauer, MD FACP, Saurabh Chhabra, MD, Marcelo C. Pasquini, MDMS, Monica Thakar, MD, Mohamed Sorror, MD MSc

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-140637

Published: 2020

Journal Articles

Impacts of Comorbidities on Outcomes of Patients (pts) Diagnosed with B-Cell Malignancies and Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative (NM) vs Myeloablative (M) Conditioning.

Mohamed Sorror, MD, MSc, Brenda M. Sandmaier, MD, Barry Storer, PhD, Michael B. Maris, MD, David G. Maloney, MD, PhD, Rainer Storb, MD

Blood (2006) 108 (11): 550.

https://doi.org/10.1182/blood.V108.11.550.550

Published: 2006

Journal Articles

The Joint Role of Comorbidity and Performance Status (PS) in Predicting Morbidity after Allogeneic Nonmyeloablative Hematopoietic Cell Transplantation (HCT).

Mohamed Sorror, MD, MSc, Barry Storer, PhD, Brenda M. Sandmaier, MD, David G. Maloney, MD, PhD, Michael Pulsipher, MD, Amelia Langston, MD, Michael B. Maris, MD, Dietger Niederwieser, MD, Rainer Storb, MD

Blood (2006) 108 (11): 596.

https://doi.org/10.1182/blood.V108.11.596.596

Published: 2006

Journal Articles

Relationship between Conditioning Intensity and Comorbidity in Patients (Pts) with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Receiving Allogeneic Hematopoietic Cell Transplantation (HCT).

Mohamed Sorror, MD, MSc, Barry Storer, PhD, Brenda M. Sandmaier, MD, Michael Maris, MD, Frederic Baron, MD, PhD, David Maloney, MD, PhD, Bart Scott, MD, H. Joachim Deeg, MD, Rainert Storb, MD

Blood (2005) 106 (11): 705.

https://doi.org/10.1182/blood.V106.11.705.705

Published: 2005

Journal Articles

Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).

Mohamed Sorror, MD, MSc, Michael Maris, MD, Barry Storer, PhD, Brenda Sandmaier, MD, Monic Stuart, MD, Ute Hegenbart, MD, Edward Agura, MD, Thomas Chauncey, MD, Jose Leis, MD, PhD, Michael Pulsipher, MD, Peter McSweeney, MD, Jerry Radich, MD, James Wade, MD, Benedetto Bruno, MD, Amelia Langston, MD, Dietger Niederwieser, MD, Karl Blume, MD, Rainer Storb, MD, David Maloney, MD, PhD

Blood (2004) 104 (11): 2323.

https://doi.org/10.1182/blood.V104.11.2323.2323

Published: 2004

Journal Articles

A Modified Hematopoietic Cell Transplantation (HCT)-Specific-Comorbidity Index.

Mohamed Sorror, MD, MSc, Maris Maris, MD, Frederic Baron, MD, Brenda Sandmaier, MD, David Maloney, MD, PhD, Rainer Storb, MD, Barry Storer, PhD

Blood (2004) 104 (11): 1146.

https://doi.org/10.1182/blood.V104.11.1146.1146

Published: 2004

NARROW

Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study

Expanded Comorbidity Definitions Improve Applicability of the Hematopoietic Stem Cell Transplantation-Comorbidity Index for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Stem Cell Transplantation

Expanded Comorbidity Definitions Improve Application of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for Children and Young Adults with Non-Malignant Diseases Receiving Allogeneic Hematopoietic Cell Transplantation

Impacts of Comorbidities on Outcomes of Patients (pts) Diagnosed with B-Cell Malignancies and Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative (NM) vs Myeloablative (M) Conditioning.

The Joint Role of Comorbidity and Performance Status (PS) in Predicting Morbidity after Allogeneic Nonmyeloablative Hematopoietic Cell Transplantation (HCT).

Relationship between Conditioning Intensity and Comorbidity in Patients (Pts) with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Receiving Allogeneic Hematopoietic Cell Transplantation (HCT).

Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).

A Modified Hematopoietic Cell Transplantation (HCT)-Specific-Comorbidity Index.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only